Display Settings:

Format

Send to:

Choose Destination
    Biotechnol Bioeng. 2009 Aug 15;103(6):1129-43.

    Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.

    Source

    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, Nebraska 68521, USA.

    Abstract

    DNA vaccines have tremendous potential for rapid deployment in pandemic applications, wherein a new antigen is "plugged" into a validated vector, and rapidly produced in a validated, fermentation-purification process. For this application, it is essential that the vector and fermentation process function with a variety of different antigen genes. However, many antigen genes are unpredictably "toxic" or otherwise low yielding in standard fermentation processes. We report cell bank and fermentation process unit operation innovations that reduce plasmid-mediated metabolic burden, enabling successful production of previously known toxic influenza hemagglutinin antigen genes. These processes, combined with vector backbone modifications, doubled fermentation productivity compared to existing high copy vectors, such as pVAX1 and gWiz, resulting in high plasmid yields (up to 2,220 mg/L, 5% of total dry cell weight) even with previously identified toxic or poor producing inserts.

    Copyright 2009 Wiley Periodicals, Inc.

    PMID:
    19408315
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2735187
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 2
    Figure 1
    Figure 3

      Supplemental Content

      Icon for John Wiley & Sons, Inc. Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk